Back to search

Aristotle University Of Thessaloniki (AUTH)

Η πρωτεΐνη MreB ως νέος αντιβιοτικός στόχος: in vitro χαρακτηρισμός της αντιμικροβιακής και κυτταροτοξικής δράσης του MreB-αναστολέα Α22 σε συνδυασμό με συμβατικά αντιβιοτικά έναντι Gram-negative κλινικών στελεχών

Abstract

dc:description

In the era of antibiotic resistance, the bacterial cytoskeletal protein MreB is presented as a potential target for the development of novel antimicrobials. Combined treatments of clinical antibiotics with anti-MreB compounds may be promising candidates in combating the resistance crisis, but also in preserving the potency of many conventional drugs. Among MreB inhibitors, A22 hydrochloride (A22) has been reported as a lead compound with potent antibacterial and antibiofilm activity but its combined activity with conventional antibiotics has not been characterized. Based on the promising background and the desirable properties of this drug, our study was dedicated to examining potential synergism between A22 and clinical used antibiotics against both planktonic and biofilm forms of multidrug resistant Gram negative bacteria, considering their hemolytic and cytotoxic activity, as well as the emergence of bacterial resistance. According to our results, Pseudomonas aeruginosa and Escherichia coli isolates were resistant to conventional antibiotics to varying degrees. A22 inhibited the bacterial growth in a dose dependent manner with MIC (Minimum Inhibitory Concentration) values ranging between 2 and 64 μg/ml. Treatment with A22 at sub-MIC and non bactericidal concentrations leads to the formation of spherical cells with damaged membranes. We found that A22 exhibited great synergistic growth inhibitory effects with various antibiotics and no antagonism was observed with any of the combinations. In combination studies, the synergistic effects were strain-dependent and synergism occurred most frequently with A22 + ceftazidime, meropenem, gentamicin and ciprofloxacin against Pseudomonas aeruginosa and A22 + azithromycin, ceftazidime and cefoxitin against Escherichia coli. The results of the combinational time-kill assays showed great synergistic bactericidal interactions with all expected combinations at 24 h of combined treatment, inducing a long post-antibiotic effect. MTT (Methyl Thiazol Tetrazolium) and confocal laser scanning microscopy studies show that synergistic combinations even at the lowest tested concentrations were able to inhibit biofilm formation and eradicate mature biofilms in both strains. A22 combined treatment inhibited the production of Quorum-sensing related extracellular virulence factors (protease, elastase, pyocyanin and ramnolipid) of clinical P. aeruginosa isolates, as well as their swarming and swimming motility. A22 either as a single agent or in combination showed a minimal cytotoxic activity against human cancer cell lines and human PBMC and PMN cells, as well as selective hemolytic properties toward human erythrocytes. In addition, relative to A22 alone, the combination of A22 with antibiotics significantly reduces or eliminates the detectable emergence of resistance. Combined application of A22 resulted in MPC (Mutant Prevention Concentration) reductions with a narrow mutant selection window. The findings of the present study support previous research regarding the use of MreB as a novel antibiotic target and also provide new insights into the potential of MreB as a target for novel therapeutics designed to prevent and disrupt biofilm formation. The obtained data expand the existing knowledge about the antimicrobial and antibiofilm activity of the A22 inhibitor and concluded that A22 exhibits synergistic antibacterial and antibiofilm properties with low cytotoxic and hemolytic effects. Overall, our results provide new evidence that MreB may take a place as a novel antibiotic target not only for single but also for combined antimicrobial therapy and indicate that A22 can serve as a leading compound for studying potential synergism between MreB inhibitors and antibiotics in the future.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2023

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Kotzialampou, Anastasia
  • Κοτζιαλάμπου, Αναστασία

Subjects

dc:subject × 14

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/53542

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Kotzialampou, Anastasia; Κοτζιαλάμπου, Αναστασία. Η πρωτεΐνη MreB ως νέος αντιβιοτικός στόχος: in vitro χαρακτηρισμός της αντιμικροβιακής και κυτταροτοξικής δράσης του MreB-αναστολέα Α22 σε συνδυασμό με συμβατικά αντιβιοτικά έναντι Gram-negative κλινικών στελεχών. Aristotle University Of Thessaloniki (AUTH), 2023. http://hdl.handle.net/10442/hedi/53542